Given the limited therapeutic options and poor prognosis of human IPF, lack of optimal animal models that recapitulate the human disease, biological plausibility of a potential benefit for mTOR inhibition in this disease, and the clinical availability of mTOR inhibitors, a case can be made to test this drug in a pilot study in human IPF. This evidence concerns the gene MTOR and idiopathic pulmonary fibrosis.